Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell
• The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
60 Biggest Movers From Yesterday
Gainers
Cyngn Inc. (NASDAQ: CYN) shares jumped 96.3% to close at $2.12 on Thursday after the company announced the official launch of DriveMod Kit, a turnkey autonomous vehicle solution.
Guggenheim Maintains Buy Rating for Rubius Therapeutics, Lowers Price Target To $5
Guggenheim has decided to maintain its Buy rating of Rubius Therapeutics (NASDAQ:RUBY) and lower its price target from $25.00 to $5.00.
Shares of Rubius Therapeutics are trading down 24.14% over the last 24 hours, at $2.42 per share.
Morgan Stanley Maintains Equal-Weight on Rubius Therapeutics, Lowers Price Target to $4
Morgan Stanley analyst Jeffrey Hung maintains Rubius Therapeutics (NASDAQ:RUBY) with a Equal-Weight and lowers the price target from $15 to $4.
Guggenheim Maintains Buy on Rubius Therapeutics, Lowers Price Target to $5
Guggenheim analyst Michael Schmidt maintains Rubius Therapeutics (NASDAQ:RUBY) with a Buy and lowers the price target from $25 to $5.
HC Wainwright & Co. Maintains Buy on Rubius Therapeutics, Lowers Price Target to $15
HC Wainwright & Co. analyst Andrew Fein maintains Rubius Therapeutics (NASDAQ:RUBY) with a Buy and lowers the price target from $40 to $15.